WO2001056545A3 - Sustained-release microencapsulated delivery system - Google Patents

Sustained-release microencapsulated delivery system Download PDF

Info

Publication number
WO2001056545A3
WO2001056545A3 PCT/US2001/003358 US0103358W WO0156545A3 WO 2001056545 A3 WO2001056545 A3 WO 2001056545A3 US 0103358 W US0103358 W US 0103358W WO 0156545 A3 WO0156545 A3 WO 0156545A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained
oil
mixer
release
degrees
Prior art date
Application number
PCT/US2001/003358
Other languages
French (fr)
Other versions
WO2001056545A2 (en
Inventor
Eric H Kuhrts
Original Assignee
Eric H Kuhrts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eric H Kuhrts filed Critical Eric H Kuhrts
Priority to AU2001234746A priority Critical patent/AU2001234746A1/en
Publication of WO2001056545A2 publication Critical patent/WO2001056545A2/en
Publication of WO2001056545A3 publication Critical patent/WO2001056545A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Disclosed is a process for producing sustained-release powders that is fast, efficient, and economical. The process involves melting an animal or vegetable oil with a melting point above 110 degrees F in specially designed mixer through either the work energy input of the mixer shaft itself, or a specially fitted plow type mixer equipped with a heating tank, cooling unit, jacket for hot water circulation, and heated lines with nozzles for atomizing the hot oil to be sprayed on. The entire manufacturing process can be completed in about 5-30 minutes, and results in small, sustained-release particles that are free flowing and solid at room temperature. The preferred oil is a hydrogenated soy oil with a melting point range of 145-160 degrees F. which is applied at about a 5% level by weight in a high shear mixer. Also included are sustained-release compositions for therapeutic agents such as drugs, botanicals, biological agents, fungicides, and fertilizers.
PCT/US2001/003358 2000-02-01 2001-02-01 Sustained-release microencapsulated delivery system WO2001056545A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001234746A AU2001234746A1 (en) 2000-02-01 2001-02-01 Sustained-release microencapsulated delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/495,556 2000-02-01
US09/495,556 US6953593B2 (en) 2000-02-01 2000-02-01 Sustained-release microencapsulated delivery system

Publications (2)

Publication Number Publication Date
WO2001056545A2 WO2001056545A2 (en) 2001-08-09
WO2001056545A3 true WO2001056545A3 (en) 2001-12-06

Family

ID=23969082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003358 WO2001056545A2 (en) 2000-02-01 2001-02-01 Sustained-release microencapsulated delivery system

Country Status (3)

Country Link
US (3) US6953593B2 (en)
AU (1) AU2001234746A1 (en)
WO (1) WO2001056545A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101626694B (en) * 2007-02-14 2013-03-13 西拉有限公司 A product based on conjugated linoleic acid and a method for the manufacture thereof

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US20040219240A1 (en) * 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US20040047967A1 (en) * 2001-08-06 2004-03-11 John Macdonough Concentrated kavalactone beverage compositions
GB0120887D0 (en) * 2001-08-29 2001-10-17 Sahajanand Biotech Private Ltd Local drug delivery system in coronary stents
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20090263522A1 (en) * 2001-10-26 2009-10-22 Babish John G Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US20030228369A1 (en) * 2002-05-06 2003-12-11 Kuhrts Eric Hauser Process for conversion of high viscosity fluids and compositions thereof
US20060013870A1 (en) * 2002-05-06 2006-01-19 Kuhrts Eric H Pharmaceutical compositions of hops resins
US20040126366A1 (en) * 2002-06-04 2004-07-01 Rima Kaddurah-Daouk Methods of treating cognitive dysfunction by modulating brain energy metabolism
US20060134248A1 (en) * 2002-09-23 2006-06-22 Maye John P Hop acids as a replacement for antibiotics in animal feed
EP1558271A4 (en) * 2002-10-21 2006-01-11 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
DE10311585A1 (en) * 2003-03-14 2004-09-23 Basf Ag Adsorbates for use in human or animal nutrition or cosmetics are produced by introducing material to be adsorbed together with stabilizer on to carrier
DK2204168T3 (en) 2003-04-07 2015-04-07 Supernus Pharmaceuticals Inc Tetracycline for administration once a day
BRPI0409032A (en) 2003-04-10 2006-05-02 Pr Pharmaceuticals method for the production of emulsion-based microparticles
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
PE20050202A1 (en) 2003-05-12 2005-05-14 Dasan Medichen Co Ltd THE CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF PSEUDOEPHREDINE OR ITS SALTS
AU2004283065B2 (en) 2003-05-22 2009-11-26 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
EP1651136B1 (en) * 2003-07-15 2017-03-08 Evonik Corporation Method for the preparation of controlled release formulations
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US7507396B2 (en) 2003-10-17 2009-03-24 Amerilab Technologies, Inc. Effervescent composition and method of making an effervescent composition including a viscous component
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd Composition and method for treatment and prevention of atherosclerosis
US20060021302A1 (en) * 2004-07-30 2006-02-02 Bernard Bobby L Anti-microbial air filter
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060067976A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
WO2006053249A2 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2
EP1814975A1 (en) * 2004-11-29 2007-08-08 Givaudan SA Substrate care product
GB0518579D0 (en) * 2005-09-12 2005-10-19 Cr Technologies Llp Controlled delivery creatine formulations and method of using the same
US20070248651A1 (en) * 2005-07-28 2007-10-25 Ellie Sawits Formulation for treatment of acne
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) * 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
AU2006304159B2 (en) * 2005-10-14 2012-09-06 Archer-Daniels-Midland Company Fertilizer compositions and methods of using
WO2007047970A2 (en) * 2005-10-21 2007-04-26 Cabot Corporation Aerogel based composites
AU2006321727A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and Acacia products
FR2894822B1 (en) * 2005-12-20 2011-11-18 Pf Medicament PHARMACEUTICAL COMPOSITION CONTAINING OMEGA-3 FATTY ACIDS
US7201929B1 (en) 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US20070160695A1 (en) * 2006-01-09 2007-07-12 Clouatre Dallas L Pharmaceutical preparations for treating hypertension and dyslipidemia with Allium ursinum and Allium sativum
US8071136B2 (en) 2006-04-21 2011-12-06 Bioactives, Inc. Water-soluble pharmaceutical compositions of hops resins
AU2007201811A1 (en) * 2006-04-24 2007-11-08 Jeffrey M Golini Sustained Release Supplements
EP2468272A1 (en) * 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
KR20090023722A (en) * 2006-06-20 2009-03-05 메타프로테오믹스, 엘엘씨 Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
US20070298079A1 (en) * 2006-06-26 2007-12-27 Tropicana Products, Inc. Food fortified with omega-3 fatty acids
US8663690B2 (en) * 2006-10-31 2014-03-04 William Marsh Rice University Method for nanoencapsulation
US9617192B2 (en) * 2006-11-13 2017-04-11 Archer-Daniels Midland Company Processes for producing weather resistant compositions and products obtained therefrom
JP5041794B2 (en) * 2006-12-07 2012-10-03 住化バイエルウレタン株式会社 Process for producing modified polyisocyanate
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
US8815306B2 (en) * 2007-03-19 2014-08-26 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
US20080269053A1 (en) * 2007-04-26 2008-10-30 Less John F Amino Acid Compositions and Methods of Using as Fertilizer
NZ581064A (en) 2007-05-11 2012-12-21 Metaproteomics Llc Methods and compositions for heavy metal detoxification
WO2009002913A1 (en) * 2007-06-22 2008-12-31 Avicena Group, Inc. Use of creatine compounds to treat dermatitis
WO2009017840A2 (en) * 2007-08-02 2009-02-05 Archer-Daniels-Midland Company Protein and isolated or purified amino acid product containing compositions and uses thereof
EP3257865A1 (en) 2007-11-16 2017-12-20 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
MX2010006425A (en) * 2007-12-10 2010-08-31 Metaproteomics Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith.
CA2720546A1 (en) * 2008-04-02 2009-10-08 Metaproteomics, Llc. Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
WO2009136410A2 (en) * 2008-04-19 2009-11-12 Nisarga Biotech Pvt. Ltd. Herbal composition for reducing add/adhd and method thereof
IE20080661A1 (en) * 2008-08-11 2010-03-03 Bk Pharma Systems Ltd Formulations for a two-phase management of wound healing and dressings incorporating such formulations.
TWI384551B (en) * 2008-10-24 2013-02-01 Ind Tech Res Inst Method for patterning crystalline indium tim oxide
CN101455655B (en) * 2009-01-04 2011-08-17 北京康比特体育科技股份有限公司 Creatine sustained-release preparation and preparation process thereof medication
US8197871B2 (en) * 2009-05-13 2012-06-12 L Europa Gary A Composition for headache treatment
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
DE102009040381A1 (en) * 2009-09-07 2011-03-17 Kallimopoulos, Thomas, Dr. Process for the isolation of alkaloids from plants
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
KR101831463B1 (en) 2010-03-26 2018-02-22 필립모리스 프로덕츠 에스.에이. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US8889157B1 (en) 2010-08-31 2014-11-18 Gary L'Europa Composition for cardiovascular treatment
PL396649A1 (en) * 2011-10-14 2013-04-15 Tomasz Banasiewicz Preventing and reducing the occurrence of uncontrolled blood sugar level drops, in patients with diabetes
WO2013063163A1 (en) 2011-10-24 2013-05-02 Kickass Candy, Llc Sweet tart energy tablet
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
CN103099787B (en) * 2013-02-19 2014-06-25 青岛正大海尔制药有限公司 Vitamin C dry suspension
US20150328162A1 (en) * 2014-05-15 2015-11-19 Mario Medri Pharmaceutical preparations
US10611983B2 (en) 2014-05-15 2020-04-07 The George Washington University Microencapsulation of chemical additives
US9907823B1 (en) 2014-11-07 2018-03-06 Eric H. Kuhrts Water-soluble phytocannabinoid formulations
RU2732502C2 (en) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Novel monoclonal antibodies to lam and pim6/lam for diagnosing and treating infections caused by mycobacterium tuberculosis
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
FR3110587B1 (en) * 2020-05-21 2022-10-14 Mixscience Pigment composition and uses thereof
CN112137109A (en) * 2020-10-14 2020-12-29 中科爱伽(天津)医用食品有限公司 Compound vegetable oil microcapsule powder for controlling weight

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
US3804776A (en) * 1970-12-14 1974-04-16 Fuji Photo Film Co Ltd Method of producing oil and fat encapsulated amino acids
WO1997010826A1 (en) * 1995-09-22 1997-03-27 Euro-Celtique S.A. Pharmaceutical formulation
US5807583A (en) * 1992-03-20 1998-09-15 Pharmacia Ab Process for the preparation of sustained release pellets
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US494681A (en) * 1893-04-04 Drive-screw
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JP2949448B2 (en) * 1992-11-30 1999-09-13 ケーヴィ ファーマセチカル カンパニー Pharmaceutical ingredients with hidden taste
FR2704146B1 (en) * 1993-04-19 1995-07-13 Cripdom Microcapsules of acetylsalicylic acid with controlled release.
EP0626172B1 (en) * 1993-05-28 2001-10-24 ASCOR CHIMICI S.r.l. Veterinary composition for treating and/or preventing infections and deseases
DE4329446A1 (en) * 1993-09-01 1995-03-02 Basf Ag Process for the production of finely divided color or active substance preparations
KR100354702B1 (en) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5458823A (en) * 1994-10-28 1995-10-17 Fuisz Technologies Ltd. Method and apparatus for spinning feedstock material
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9500863D0 (en) * 1995-01-17 1995-03-08 Grampian Pharm Ltd Medicated animal foodstuffs
PT750854E (en) * 1995-06-29 2002-04-29 Nestle Sa PROCESS FOR THE ENCAPSULATION OF A NUCLEAR MATERIAL WITH A HIGH PRESSURE TREATMENT POLYMER
US5756719A (en) * 1996-09-03 1998-05-26 Basf Corporation Double emulsion techniques for making novel compositions containing gluten and polysaccharides that contain uronic acid residues useful for encapsulating fats, oils and solids
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
US3804776A (en) * 1970-12-14 1974-04-16 Fuji Photo Film Co Ltd Method of producing oil and fat encapsulated amino acids
US5807583A (en) * 1992-03-20 1998-09-15 Pharmacia Ab Process for the preparation of sustained release pellets
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
WO1997010826A1 (en) * 1995-09-22 1997-03-27 Euro-Celtique S.A. Pharmaceutical formulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical excipients, 3rd edition", 2000, KIBBE A. H., WASHINGTON, XP002172955 *
"Handbook of Pharmaceutical Excipients, 3rd edition", 2000, KIBBE A. H., WASHINGTON, XP002172956 *
LIDE D, R: "CRC Handbook of Chemistry and Physics", 1995, BOCA RATON, XP002172911 *
TAGGART ET AL.: "The evaluation of formulation and processing conditions of a melt granulation process", INTERNATIONAL JOURNAL OF PHARMACEUTICS, XP001010672 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101626694B (en) * 2007-02-14 2013-03-13 西拉有限公司 A product based on conjugated linoleic acid and a method for the manufacture thereof

Also Published As

Publication number Publication date
US20020086062A1 (en) 2002-07-04
US20060068021A1 (en) 2006-03-30
US20020098239A1 (en) 2002-07-25
WO2001056545A2 (en) 2001-08-09
US6953593B2 (en) 2005-10-11
US6689388B2 (en) 2004-02-10
AU2001234746A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
WO2001056545A3 (en) Sustained-release microencapsulated delivery system
WO2007002946A3 (en) Devices, systems and methods for rapid endovascular cooling
TW351749B (en) System for the treatment of chemical wastes and method for treating chemical wastes
CA2036780A1 (en) Method for the preparation of sweetening agent delivery systems containing polyvinyl acetate
PT1695602E (en) Agricultural machine for incorportating liquid substances into soil
WO2006127298A3 (en) Method of producing suspended agricultural chemical composition
CN103816060A (en) Massage oil wax and preparation method thereof
WO2002001960A3 (en) Device and method for the thermal treatment of unshelled eggs
CN101411701A (en) Vitamin C microcapsule formulation and preparation method thereof
FR2656526B1 (en) CONTROLLED RELEASE DEVICE AND PREPARATION METHOD.
WO2000072685A8 (en) Method for producing bactericide
EP1103775A3 (en) Heat exchanger and water heating system using same
CN106614021A (en) Environment-friendly agglomerate type cat litter and preparation method thereof
AU2002222283A1 (en) Fat replacement material and method of manufacture thereof
Weiser et al. Modeling of Complex Composite Parts Utilizing Modified Silicone Rubber Tooling
Wanner Effects of light, temperature, fertilizers and pesticides on shell size of the common freshwater and soil species Cyclopyxis kahli(Rhizopoda, Testacealobosia)
CN107232190A (en) Clothianidin controlled release embedded particles agent and its preparation and application
DE60210931D1 (en) METHOD FOR THE TREATMENT OF SOLVENT EXTRACTED PLANT SMALL PARTS WITH A FAT
DE102006026062A1 (en) Production of powdered, fat enriched substance e.g. milk substitute product useful as a feed for human and calves, comprises spraying fat enriched medium to droplets in fluid condition in cold atmosphere and cooling the medium
JPS6157504A (en) Release speed control medicine and use
Radivojević et al. Production of compost from solid cattle manure in conditions of PKB
JPS57130808A (en) Air conditioner for automobiles
CN110205212A (en) A kind of multi-function health-care soap and preparation method thereof
WO2005007280A3 (en) Method for preparing a microdispersion of wax
JP2680322B2 (en) Method for producing powdery fat and oil composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP